Skip to content

Comparison of Intravenous Tegileridine vs. Hydromorphone on Postoperative Nausea and Vomiting Incidence Following Laparoscopic Surgery: A Prospective Randomized Controlled Study

Comparison of Intravenous Tegileridine vs. Hydromorphone on Postoperative Nausea and Vomiting Incidence Following Laparoscopic Surgery: A Prospective Randomized Controlled Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108695
Enrollment
Unknown
Registered
2025-09-03
Start date
2025-09-08
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PONV,postoperative nausea and vomiting

Interventions

Group T:Perioperative Use of Tegileridine for Analgesia
Group H:Perioperative Use of Hydromorphone for Analgesia

Sponsors

Zhongshan Hospital ( Xiamen ) , Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 18 years = 3; 5. Voluntarily participate and provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe dysfunction of major organs (e.g., AV block above first degree without pacemaker, left ventricular ejection fraction <40%, coronary artery disease, myocardial infarction, hepatic or renal insufficiency, Parkinson's disease, Alzheimer's disease, seizure disorders, epilepsy); 2. Chronic pain (defined as pain persisting or recurring for more than 3 months); 3. Preoperative use of sedatives or analgesics (any sedative-hypnotic agents such as benzodiazepine and non-benzodiazepine receptor agonists, or opioid medications including morphine, fentanyl, and oxycodone); 4. Patients with known allergies to related drugs; 5. Patients unable to cooperate with postoperative follow-up or with communication barriers; 6. Pregnant or lactating women; 7. Patients with inadequate obtainment of medical history; 8. Patients who refuse to participate in the study.

Design outcomes

Primary

MeasureTime frame
The incidence of postoperative nausea and vomiting ;

Secondary

MeasureTime frame
The incidence of postoperative nausea and vomiting (PONV) ;The incidence of severe postoperative nausea and vomiting (PONV) and rescue treatments ;Postoperative analgesic efficacy ;Quality of Recovery (QoR) and Patient Satisfaction;Postoperative EQ-5D-3L Scores;Postoperative anesthetic complications;

Countries

China

Contacts

Public ContactChao Liang

Zhongshan Hospital ( Xiamen ) , Fudan University

superwm226@126.com+86 159 2167 9955

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026